Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 8.45
- Piotroski Score 3.00
- Grade Buy
- Symbol (BHVN)
- Company Biohaven Pharmaceutical Holding Company Ltd.
- Price $50.98
- Changes Percentage (-0.39%)
- Change -$0.2
- Day Low $50.24
- Day High $51.61
- Year High $62.21
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $59.00
- High Stock Price Target $68.00
- Low Stock Price Target $23.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.90
- Trailing P/E Ratio -4.88
- Forward P/E Ratio -4.88
- P/E Growth -4.88
- Net Income $-408,168,000
Income Statement
Quarterly
Annual
Latest News of BHVN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Biohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo Finance
Biohaven Ltd. released positive results from Study BHV4157-206-RWE, showing troriluzole's efficacy in improving f-SARA scores after 3 years of treatment for Spinocerebellar Ataxia (SCA), a rare neurod...
By Yahoo! Finance | 6 days ago
